Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

Exclusion Criteria

• •Diabetes mellitus if newly diagnosed or if glycated hemoglobin (HbA1c) \>= 9.0%.
• •Active pancreatitis within 2 weeks of screening.
• •Acute coronary syndrome within 6 months of screening.
• •Major surgery within 3 months of screening.
• •Treatment with Glybera therapy within 2 years of screening.
• •Previous treatment with AKCEA-ANGPTL3-LRx.
• •Have any other conditions in the opinion of the investigator which could interfere with the patient participating in or completing the study.